Fludarabine

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

Size Price Stock Quantity  
In DMSO USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

5 Customer Reviews

  • Br J Cancer, 2018, 118(4):509-521. Fludarabine purchased from Selleck.

    ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

  • Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

    Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

  • Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  MX;GeY5kfGmxbjDBd5NigQ>? M4DnOFIxKM7:TR?= MYmyOEBp NVPVVG9UcW6qaXLpeJMh\XiycnXzd4lwdiCxZjDJSG8> NWTFO4VOOjV7NEC3NVI>
MV-4-11 NWDYbppNSXCxcITvd4l{KEG|c3H5 MnLKNk42KM7:TR?= Ml:4OFghcA>? M4TmZolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NX;PR4FLOjVzMUG1PFM>
THP-1 NYHONJM2SXCxcITvd4l{KEG|c3H5 M4O3RVIvPSEQvF2= M3ywTlQ5KGh? MlHKbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= M4H0blI2OTFzNUiz
MOLM 13 MV7BdI9xfG:|aYOgRZN{[Xl? NYGzdoREOi53IN88US=> M2THblQ5KGh? M3\IVIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MUmyOVEyOTV6Mx?=
KBM3/Bu2506 NXPkPGViSXCxcITvd4l{KEG|c3H5 NX\SWZY1Oi53IN88US=> MlvVOFghcA>? M33ydolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 M3zDc|I2OTFzNUiz
Nalm-6 NIPzSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjObmtiUUN3ME2xPEDPxE1? MYGyOVA3OTFyMR?=
Reh NFjxSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrEc4hWUUN3ME2zNEDPxE1? NHH1VYMzPTB4MUGwNS=>
U2937 M1i1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPROnVnUUN3ME2xOkDPxE1? NYTUNJl2OjVyNkGxNFE>
Mec-1 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPkXI5KSzVy78{eOVAxKM7:TR?= M2XFd|I2ODZzMUCx
RPMI-8226 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC4PGFzUUN3ME21NFAh|ryP NF3tNpIzPTB4MUGwNS=>
Molt-4 M2TM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknyTWM2OD1zOECg{txO NHHD[4czPTB4MUGwNS=>
Nalm-6-FluR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LO[WlEPTB;MkWwJO69VQ>? MnGzNlUxPjFzMEG=
Raji  NELwR4hHfW6ldHnvckBCe3OjeR?= MlXuN:Kh|ryP MXiyOE81QC95MjDo NIDHU|NqdmS3Y3XzJIFk[3WvdXzheIlwdnNib3[gdFU{NCCyNkOgZY5lKHB5M9Mg NVnmOJh2OjR7NEC2PVU>
PBMC M1fXeGZ2dmO2aX;uJGF{e2G7 M{nYXFUxNzFyMDFOwG0> MoLSNlQhcA>? MV\EUXNQ MUTpcohq[mm2czDTWGFVOSCyaH;zdIhwenmuYYTpc44> M3\XWVI1QTFzOEey
MDA-231 NGftVG5HfW6ldHnvckBCe3OjeR?= NUXWUHRMOTByIN88US=> NG\lTpMzPCCq NEHybnFFVVOR Moez[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w NYPrPGp5OjR7MUG4O|I>
624.38mel  MnfiSpVv[3Srb36gRZN{[Xl? NFvmOYU2OCEQvF2= NIrHVnIzPCCq NFHhb4FFVVOR MXzk[YNz\WG|ZYOgTWRQKGW6cILld5Nqd25? MYOyOFkyOTh5Mh?=
MDA-231 NGH4R5RHfW6ldHnvckBCe3OjeR?= MoHROVAuOjByIN88US=> NGHDPVYzPCCq NFP0[4pFVVOR M33Od4lvcGmkaYTzJGlFVyCjY4Tpeol1gSCrbnTldIVv\GWwdHz5JI9nKG2UTlGgcIV3\Wy| MW[yOFkyOTh5Mh?=
624.38mel  NHvYU4hHfW6ldHnvckBCe3OjeR?= NUPWemFuPTBvMkCwJO69VQ>? M{DwTlI1KGh? Mo\iSG1UVw>? NF\1[ZVqdmirYnn0d{BKTE9iYXP0bZZqfHliaX7k[ZBmdmSnboTsfUBw\iCvUl7BJIxmfmWucx?= NFrS[oEzPDlzMUi3Ni=>
HMECs MkDmSpVv[3Srb36gRZN{[Xl? M2jEdVExOMLizszNxsA> MlfoN|bDqGh? M17nbYlvcGmkaYTzJGlHVs7|wrDhcoQhVFCVIHnu[JVk\WRiU2TBWFEheGixc4Doc5J6dGG2aX;uJIFv\CCLUl[xJIV5eHKnc4Ppc44> M3nU[FI1OjFzM{K3
HMECs  NYjr[Yg2TnWwY4Tpc44hSXO|YYm= M3WwblExOMLizszNxsA> NYCyWZhCOzcEoHi= MVzpcohq[mm2czDJSm7PucLibXXkbYF1\WRicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKGGwZDDTWGFVOyxiYoX0JI5wfCCxZjDTWGFVOg>? MoHiNlQzOTF|Mke=
BJAB MnPJRZBweHSxc3nzJGF{e2G7 NHzBcIU2yqEQvF2= NWHCXHo{OjRiaB?= NYLrS5VycW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MUeyOFA2PzF2Nx?=
I-83 NF\FVnpCeG:ydH;zbZMhSXO|YYm= NEizTVU2yqEQvF2= NXrjNmlZOjRiaB?= MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUeyOFA2PzF2Nx?=
NALM6 MW\BdI9xfG:|aYOgRZN{[Xl? M2LYN|XDqM7:TR?= MmrPNlQhcA>? NEHhSJlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NUPTOHhiOjRyNUexOFc>
DU-145 NIHrNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqwMVExKM7:Zz;tcC=> M3LBNVQ5KGkEoB?= NGXnVYhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlzmNlM4OzR6MUW=
Nalm-6 NFPWdJhHfW6ldHnvckBCe3OjeR?= M4TYdFExyqEQvF2= MX6xM|IwPCCq NF74WXNqdmS3Y3XzJIF2fG:yaHHnfS=> MWSyN|Y5OTJ{Mx?=
Reh NEjWUm5HfW6ldHnvckBCe3OjeR?= M2PheVExyqEQvF2= MoXXNU8zNzRiaB?= M3nxT4lv\HWlZYOgZZV1d3CqYXf5 NH3IN3YzOzZ6MUKyNy=>
Nalm-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDmS2ZKSzVyIPMIwFEx6oDLzszN MkXmNlM3QDF{MkO=
Reh NGPEXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK4TWM2OCEkiMyxNQKBkc7:TR?= M3;1W|I{PjhzMkKz
HEC1A NFfLfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNFAuPTByIN88US=> MYGyOEBp MkDvbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWrsbFV[OjN3OUW2PVc>
AN3CA MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW2NVAxNTVyMDFOwG0> M2nDc|I1KGh? NUG1[JFzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX\ZeHVpOjN3OUW2PVc>
HEC50B NXnQeINmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7VRZAyODBvNUCwJO69VQ>? NWHRSXNsOjRiaB?= M3O2VIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 MYGyN|U6PTZ7Nx?=
HEC1A NH\zVmhCeG:ydH;zbZMhSXO|YYm= NIDVVVUzOC9zMECg{txO M4[4eFI1KGh? M3XoTolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHPENoUzOzV7NU[5Oy=>
AN3CA MXPBdI9xfG:|aYOgRZN{[Xl? MUWyNE8yODBizszN NX;BfWVCOjRiaB?= M{WxdYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MoPoNlM2QTV4OUe=
HEC50B M3nTeWFxd3C2b4Ppd{BCe3OjeR?= M4PPTlIxNzFyMDFOwG0> NEXiUXIzPCCq M2O1dYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MX6yN|U6PTZ7Nx?=
EHEB NGD6Wo9CeG:ydH;zbZMhSXO|YYm= MXm0NEDPxE1? NWrleoxSOjRiaB?= MUjpcoR2[2W|IHHwc5B1d3Orcx?= MnzzNlM1QTdyN{W=
A549 NV;odGZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT6e|JyUUN3ME2xOU44yrF{LkigxtVO NGfoS4czOzN5N{G5Ni=>
A549 GAPDH-deficient Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e5cGlEPTB;MUiuOeKyOi5|INM1US=> NE\BPZkzOzN5N{G5Ni=>
CLL  M3L5O2Fxd3C2b4Ppd{BCe3OjeR?= M4CwXlExKM7:TdMg MYqyOE06PiCq NXe5fm9XcW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? Moi3NlIzODd4OE[=
MEC1 M3TnbWFxd3C2b4Ppd{BCe3OjeR?= M1jMbVExOMLizszN NGHqVVg4OiCq MUnpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MVOyNlE{Ojl5Mx?=
U937  NWPZO296SXCxcITvd4l{KEG|c3H5 MmeyNE45KM7:TR?= MYm0MVQ5KGh? NFm2dI9qdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NVvqeJI3OjJyN{S3NFA>
U937  MVjBdI9xfG:|aYOgRZN{[Xl? MlXhNUDPxE1? Mmr4PVYhcA>? MYHpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MkjSNlIxOjN3MkO=
Daudi NVrjSpBxSXCxcITvd4l{KEG|c3H5 M4PQZlIxKM7:TR?= NHW2T4Q6PiCq NXzBVHdVcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> NEDKXm8zOjB{M{WyNy=>
J45.01 NGCwXnpCeG:ydH;zbZMhSXO|YYm= MXuxJO69VQ>? M1fj[Vk3KGh? MVXpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NUTmZ3hXOjJyMkO1NlM>
RPMI 8226 NWG2bm1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\0TWM2OD1{NT65xsDDucLiMz63JO69VQ>? NXL4cm9mOjF7NEiyOlQ>
CEM MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwNNMgxtHDqDBwNDFOwG0> MW[yNVk1QDJ4NB?=
Raji MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwNEhCpOKyyqByLkC0JO69VQ>? MXuyNVk1QDJ4NB?=
U937 M3rNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDF[GVKSzVyPUCuNlTDqMLzwrCwMlA1KM7:TR?= Mke1NlE6PDh{NkS=
K562 NGTiVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7ZTWM2OD1yLkS0xsDDucLiMD6wOUDPxE1? MUWyNVk1QDJ4NB?=
NALM-6 NHrae21CeG:ydH;zbZMhSXO|YYm= M{LzPVExKM7:TdMg MXuyOEBp NHfHemdqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPsbYdpfGy7 NWr3OnpLOjF4OUmzPFM>
JMV-3 MVPBdI9xfG:|aYOgRZN{[Xl? MV2xNEDPxE4EoB?= MXWyOEBp NWPNWFd2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?= MmL6NlE3QTl|OEO=
EHEB NI[yRmdHfW6ldHnvckBCe3OjeR?= MXK1MVUxKM7:TR?= NE\wVlQzPCCq MWLk[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> MlXhNlEyPjh|OUG=
JVM-2  NWHnXW5JTnWwY4Tpc44hSXO|YYm= NWPaR25MOzBizszN NVLqVIpHOjRiaB?= NGLBO5dl\WO{ZXHz[ZMheDJzIHX4dJJme3Orb36= MUWyNVE3QDN7MR?=
KBM3/Bu2506 NWOxeGNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELmXXdKSzJyPUCuOlchyrWP M2e1UlIxQTN|NUC5
KBM3/Bu2506 NHjUVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[wMlYh|ryP Mmf0NlQhcA>? M{DI[Ilv[3KnYYPld{B1cGViY3XscEBnemGldHnvckBqdiCVLYDoZZNm NYntSpRvOjB7M{O1NFk>
MDA-MB-231 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXrZZZWUUN3ME20MlAh|ryP NX3lTHBHOjB2NEezPVA>
MCF-7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[3UZFKSzVyPUG1MlAh|ryP NWfRUIFUOjB2NEezPVA>
HLE-B3  NH3hZXRHfW6ldHnvckBCe3OjeR?= NEf6elczPSEQvF2= NWK2fW1SPDhiaB?= MVLicI9kc3NiSV\OMe6{6oDVaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmGTzDlfJBz\XO|aX;u Mnj2NlA1OzVzNUi=
K562 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vvblczKGh? Mn7FTWM2OD1|LkOgcm0> MX6yNFMxPzF7OB?=
BW-225 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu3SVVKSzJyPUGuN|chy5dzMPMIlljDqM7:TdMg NE[4XHYyQDZ4MUO4NC=>
OH-65 M136WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jPNGlEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= NHHpNowyQDZ4MUO4NC=>
GR-145 NVHlWIFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLkWo1IUUN{ME2yMlc1KMPZIEGw5qiTQCBizszNxsA> NYTnfVd2OTh4NkGzPFA>
A549 M{m1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHQVWJKSzJyPUWuOFghy5diMUFijLI5KM7:TdMg M{TQfVE5PjZzM{iw
CaSki  NVrKXmVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fZVGlEOjB;MT6zO{DEnyBzMPMIllch|ryPwrC= Mn75NVg3PjF|OEC=
ZMK-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\ZWZBFUUN{ME2xMlM4KMPZIEGw5qiTPiEQvF5CpC=> MWKxPFY3OTN6MB?=
SKW6.4 NHXpcXVCeG:ydH;zbZMhSXO|YYm= NVzVWm57OC5yMT2xNEDPxE1? NF[3Z4czPC92ODDo MnHrbY5lfWOnczDj[YxtKGSnYYToJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? M3;zTVE5ODl{M{Sw
RPMI 8226 NWq2T4NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUeyOEBp NWfk[mhnUUN3ME2xMlU1yqEQvF2= NHPyO4MyPzl5NkG4Oi=>
MM.1S M1;NSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;QW|Q5KGh? NUXiXmpMUUN3ME2xN{41QMLizszN NILDboYyPzl5NkG4Oi=>
MM.1R NH3FNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYC0PEBp NFnZXWxKSzVyPUOzMlc6KM7:TR?= MWexO|k4PjF6Nh?=
U937 Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XkPWlEPTB;MzyyNFAhyrFiNU[wJI5O M3HsSlE2QTNyM{[x

... Click to View More Cell Line Experimental Data

In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Formulation: PBS
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03579888 Not yet recruiting Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|Ziopharm Oncology|Precigen Inc December 2019 Phase 1
NCT03579888 Not yet recruiting Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|Ziopharm Oncology|Precigen Inc December 2019 Phase 1
NCT03873805 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 City of Hope Medical Center|National Cancer Institute (NCI) August 1 2019 Phase 1
NCT03873805 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 City of Hope Medical Center|National Cancer Institute (NCI) August 1 2019 Phase 1
NCT03710421 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma City of Hope Medical Center|National Cancer Institute (NCI) June 10 2019 Phase 1
NCT03856216 Not yet recruiting Acute Lymphoblastic Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation Recipient|B Acute Lymphoblastic Leukemia|CD22 Positive|Lymphocytic Neoplasm|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) June 30 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products0

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID